Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. More Details
+ 1 more risk
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Imugene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMU is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IMU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
1 Year Return
Return vs Industry: IMU exceeded the Australian Biotechs industry which returned -10.9% over the past year.
Return vs Market: IMU exceeded the Australian Market which returned 35.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Imugene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StA Look At Imugene's (ASX:IMU) CEO Remuneration
4 months ago | Simply Wall StAnnouncing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years
6 months ago | Simply Wall StWhat Can We Conclude About Imugene's (ASX:IMU) CEO Pay?
Is Imugene undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMU's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMU's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMU is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: IMU is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMU is overvalued based on its PB Ratio (23.3x) compared to the AU Biotechs industry average (4.9x).
How is Imugene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMU's revenue (1.2% per year) is forecast to grow slower than the Australian market (4.9% per year).
High Growth Revenue: IMU's revenue (1.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMU is forecast to be unprofitable in 3 years.
How has Imugene performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMU is currently unprofitable.
Growing Profit Margin: IMU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.
Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: IMU has a negative Return on Equity (-18.68%), as it is currently unprofitable.
How is Imugene's financial position?
Financial Position Analysis
Short Term Liabilities: IMU's short term assets (A$37.1M) exceed its short term liabilities (A$3.8M).
Long Term Liabilities: IMU's short term assets (A$37.1M) exceed its long term liabilities (A$988.3K).
Debt to Equity History and Analysis
Debt Level: IMU is debt free.
Reducing Debt: IMU has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMU has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 32.8% each year
What is Imugene current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...
CEO Compensation Analysis
Compensation vs Market: Leslie's total compensation ($USD567.17K) is below average for companies of similar size in the Australian market ($USD948.74K).
Compensation vs Earnings: Leslie's compensation has been consistent with company performance over the past year.
Experienced Management: IMU's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: IMU's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.
Imugene Limited's company bio, employee growth, exchange listings and data sources
- Name: Imugene Limited
- Ticker: IMU
- Exchange: ASX
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$1.268b
- Shares outstanding: 4.79b
- Website: https://www.imugene.com
- Imugene Limited
- 37 Bligh Street
- Suite 1006
- New South Wales
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 08:02|
|End of Day Share Price||2021/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.